Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Spends $1.2M to Buy Additional Alnylam Shares as Part of Companies' 2005 Alliance

Premium

Alnylam Pharmaceuticals has pocketed around $1.2 million after Novartis fully exercised its right to purchase an additional 65,922 unregistered shares of Alnylam's common stock, pursuant to the companies' 2005 drug-discovery and -development deal, Novartis said this week.

Novartis, which Alnylam lists as its second biggest shareholder, said its decision to purchase the additional stock, for which it paid $17.50 per share, allows it to maintain its current 13.4 percent stake in Alnylam.

In September 2005, the companies first announced that they had forged a three-year alliance to develop drugs based on Alnylam's RNAi technology (see RNAi News, 9/9/2005). As part of that arrangement, Novartis took what was then a 19.9 percent stake in Alnylam.

Last summer, Alnylam announced that the arrangement had been extended for an additional year and will run through October 2009 (see RNAi News, 7/17/2008).

Shares in Alnylam closed down 1.34 percent at $18.37 on Wednesday.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.